Dr. Casper said that the institute was also speaking to research institutions to relocate the work, and was also looking to license technology like the vaccines to ensure the research could continue elsewhere. Early in the institute’s history, Dr. Reed and Rhea Coler, the head of the tuberculosis vaccine program, played a role in the development of the GlaxoSmithKline vaccine. The institute also focuses on developing adjuvants, which are used in some vaccines to stimulate the body’s immune response. In the spring of 2018, the institute’s chief financial officer, general counsel, board chairman and two of its other board members resigned. He said he did not see evidence that Dr. Reed misused funds.

Source: New York Times December 13, 2019 19:52 UTC